- Home
- SONM vs KZIA Comparison
SONM vs KZIA Comparison
Compare SONM & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SONM | KZIA |
|---|---|---|
| Founded | 1999 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7M | 186.7M |
| IPO Year | 2019 | 2002 |
Fundamental Metrics
Financial Performance| Metric | SONM | KZIA |
|---|---|---|
| Price | $3.61 | $9.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.50 |
| AVG Volume (30 Days) | 15.4K | ★ 334.5K |
| Earning Date | 04-14-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.89 | N/A |
| Revenue | ★ $58,298,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.13 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.58 | $4.86 |
| 52 Week High | $12.30 | $17.40 |
Technical Indicators
Market Signals| Indicator | SONM | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 40.89 |
| Support Level | N/A | $10.37 |
| Resistance Level | N/A | $14.85 |
| Average True Range (ATR) | 0.00 | 0.70 |
| MACD | 0.00 | -0.09 |
| Stochastic Oscillator | 0.00 | 19.72 |
Price Performance
Historical ComparisonAbout SONM Sonim Technologies Inc.
DNA X Inc is engaged in providing crypto trading services through its online platform, enabling users to buy, sell, and exchange cryptocurrencies, as well as execute automated trading strategies between currency pairs. The company generates revenue from commissions and fees on trading activity.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.